Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Cheng, Lijuan; Song, Qi; Liu, Mengke; Wang, Yan; Yi, Hongmei; Qian, Ying; Xu, Pengpeng; Cheng, Shu Hsing; Wang, Chaofu; Wang, Li; Zhao, Wei

doi:10.3389/fimmu.2021.702593

Cited by 13 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three-year survival was 59% [ 27 ]. Finally, the combination of lenalidomide and the anti-PD1 monoclonal antibody tislelizumab achieved CR in a single PBL patient who was refractory to mini-CHOP and bortezomib [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma

Ryu

Ricker

Soderquist

et al. 2022

JCM

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare and aggressive form of large B-cell lymphoma (LBCL) most commonly seen in the setting of chronic immunosuppression or autoimmune disease. The prognosis is poor and CHOP-like regimens often fail to produce durable remission; therefore, there is no established standard of care treatment. However, PBL demonstrates substantial morphologic and immunophenotypic overlap with multiple myeloma (MM), suggesting that MM therapeutics might prove useful in treating PBL. We studied the effects of treatment using the first-in-class monoclonal antibody directed against CD38, daratumumab, in combination with chemotherapy in seven patients with advanced-stage LBCL with plasmablastic features. Treatment was safe and well-tolerated. Among six evaluable patients, six patients had complete response after treatment, and four patients who met strict WHO criteria for PBL had durable response (12–31 months and ongoing).

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma

Ryu

Ricker

Soderquist

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“… 28 Recently, successful management of a refractory PBL who could not tolerate miniCHOP and bortezomib was treated with tislelizumab and lenalidomide and achieved full remission, indicating immunotherapy could be the future of PBL treatment. 29 …”

Section: Discussionmentioning

confidence: 99%

Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient

Pokhrel

Yuldasheva

Mirashi³

et al. 2022

Journal of Investigative Medicine High Impact Case Reports

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a rare but aggressive subtype of diffuse large B-cell lymphoma (DLBCL). The diagnosis of PBL is challenging as its features overlap with lymphoma and myeloma. The most common presentation involves the oral cavity/jaw in human immunodeficiency virus (HIV)–positive patients. It has also been reported in the gastrointestinal (GI) tract, lymph nodes, and soft tissues. Usually, if PBL involves the GI tract, it presents as a gut tumor mass. In this report, we present an HIV-positive patient with PBL presenting with multiple peritoneal nodules. To our knowledge, this is the first case of PBL presenting as multiple peritoneal and retroperitoneal nodules in an HIV-positive patient. This case emphasizes the rare presentation of a rare malignancy, difficulties in establishing a diagnosis, and the importance of proper and timely management.

show abstract

“…In a report of salvage therapy with single agent nivolumab in a patient with PDL1+ PBL, treatment was used as a successful bridge to allogeneic stem cell transplant [ 41 ]. In another report of chemoresistant EBV + PBL, one patient treated with tislelizumab and lenalidomide, the treatment resulted in CR with total overall survival of 18 months [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Lee

Martin

Abdulhaq

2022

Case Reports in Hematology

View full text Add to dashboard Cite

Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. Gorham’s lymphangiomatosis or Gorham–Stout disease (GSD) is a rare skeletal condition of unknown etiology characterized by progressive bone loss and nonmalignant proliferation of vascular and lymphatic channels within the affected bone. Neither disease has a standard of care. We present a 23-year-old HIV-negative woman with GSD, managed medically with octreotide and sirolimus, who developed PBL. After progressing on V-EPOCH (bortezomib, etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone), she was treated with daratumumab, lenalidomide, and dexamethasone (DRD) therapy and achieved complete remission after two cycles with progression after eight cycles. This is a report of treatment of PBL with DRD therapy. Clinical investigations of the DRD regimen in PBL in conjunction with other agents to improve both depth and durability of response are warranted.

show abstract

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide

Cited by 13 publications

References 24 publications

Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma

Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma

Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient

Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature

Contact Info

Product

Resources

About